

19 December 2024

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Notification of dealings by a director/PDMR

Aptamer Group plc (AIM: APTA), the developer of novelOptimer[®] binders to enable innovation in the life sciences industry, today announces that David Bunka, Chief Scientific Officer, on 19 December 2024 purchased 1,317,870 ordinary shares of £0.001 each ("Ordinary Shares") in the Company at a price of 0.3794 pence per Ordinary Share.

Following this transaction, David Bunka's total beneficial interest in the Company is 19,842,070 Ordinary Shares, representing approximately 1.00% of the Company's issued share capital.

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the purchase of ordinary shares by directors and other PDMRs in the Company.

NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	David Bunka
2	Reason for the notification	
a)	Position/status	Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Aptamer Group plc
b)	LEI	213800Y4XGH3WJNBE686
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.001 each GB00BNRRP542
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Price 0.3794p Volume 1,317,870
d)	Aggregated information - Aggregated volume - Price	1,317,870 0.3794p
e)	Date of the transaction	19 December 2024
f)	Place of the transaction	London Stock Exchange

- Ends -

For further information, please contact:

Aptamer Group plc Arron Tolley, Chief Executive Officer	+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes	+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker	+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations Sarah Hollins	+44 (0) 113 730 3896

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

About Aptamer Group plc

Aptamer Group is a leading global developer of aptamer-based ligands that help scientists remove the limits to discovery and innovation. Leveraging a proprietary discovery and development platform, Aptamer delivers custom affinity ligands, supported with a complete suite of characterisation and validity assays that enhance the translation of its binders and optimise scientific outcomes for customers.

Aptamer's cutting-edge technology spans healthcare, research, personal care, and industrial processes, delivering new affinity solutions for novel targets, advanced diagnostics, and precision therapies. By working with industry leaders in pharmaceutical, biotechnology, personal health, academic, and clinical research sectors, Aptamer is accelerating science through the custom development of tools and therapies.

To register for news alerts by email go to <https://aptamergroup.com/investors/investor-news-email-alerts/>.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHTLBFTMTIBBJI